Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Hemophilia Market 2016 Overview, Trend and Analysis

Friday, November 18, 2016 3:18
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Hemophilia refers to a set of hereditary genetic disorders that impairs the body’s ability to control blood clotting, which controls bleeding when a blood vessel is broken. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. In the absence of a treatment, uncontrolled internal bleeding can occur, causing stiffness, pain, severe joint damage and even death. Depending upon the coagulation factor deficiency, there are different types of hemophilia such as Hemophilia A, Hemophilia B, Hemophilia C, Von Willebrand disease and Hemophilia with Inhibitors.

Even though Hemophilia is rare bleeding disorder, the number of people affected by it has been increasing with time. While mild hemophilia is easy to diagnose especially in kids, when they learn to move and walk, and get large bruises from minute falls, severe hemophilia patients need to go for periodic transfusion of the respective factors so as to avoid the event of life-threatening bleeding episodes. Such a periodic transfusion is done through what is commonly known as the replacement therapy. With increasing sophistication and modernization of technology, demand for advanced treatment options increases, thereby making the entire market grow.
For more information about this report http://www.reportsweb.com/global-hemophilia-market-report-2016-edition

The key factors which are anticipated to drive this market include increasing penetration of recombinant factor VIII, increasing healthcare expenditure, emerging use of treatments in low income countries and increasing diagnosis rates. Some of the noteworthy progresses of this industry include the increasing adoption of prophylaxis therapy, introduction of extended half-life products and gene therapy. However, the growth of respective industry is challenged by the high cost of treatments and high reluctance by patients to switch to new treatments/products.

The report provides a comprehensive study of global hemophilia market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global hemophilia industry is highly competitive consisting of several large companies including the Shire Plc, Bayer Group, Pfizer Inc, Novo Nordisk etc. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.  

Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001187428/sample .

  Company Profiles 

5.1 Shire PLC 
5.1.1 Business Overview 
5.1.2 Financial Overview 
5.1.3 Business Strategies 
5.2 Bayer Group 
5.2.1 Business Overview 
5.2.2 Financial Overview 
5.2.3 Business Strategies 
5.3 Novo Nordisk 
5.3.1 Business Overview 
5.3.2 Financial Overview 
5.3.3 Business Strategies 
5.4 Pfizer Inc. 
5.4.1 Business Overview 
5.4.2 Financial Overview 
5.4.3 Business Strategies 

Make an enquiry: http://www.reportsweb.com/inquiry& RW0001187428/buying .

Contact Us:

Call: +1-646-491-9876
Email: sales@reportsweb.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.